OncoSec Medical's Intratumoral Plasmid IL-12 Demonstrates Effectiveness At Enhancing Tumor Immunogenicity In Preclinical Tumor Models
SAN DIEGO, March 21, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented a poster titled "Intratumoral Electroporation-mediated IL-12 Gene Therapy Can Enhance Tumor Immunogenicity" (Poster #2074), at the Keystone Symposia Conference, "Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology," in Whistler, British Columbia, Canada. The poster included preclinical data demonstrating that in vivo electroporation of intratumoral plasmid IL-12 (ImmunoPulse® IL-12) enhances immunogenicity in poorly immunogenic mouse cancer models. For more information about this meeting, please visit http://keystonesymposia.org.
"These data support the hypothesis that intratumoral delivery of plasmid IL-12 with electroporation can alter the tumor's immune environment in such a way that a 'cold' non-immunogenic tumor is converted to a 'hot' immunogenic tumor, thus further supporting recent clinical data that ImmunoPulse IL-12 is a rational combination therapy with anti-PD-1 checkpoint therapies," said Punit Dhillon, President and CEO. "Also, generation of an antigen-specific CD8 T-cell response provides evidence for a potential mechanism of action for the abscopal responses seen in both preclinical and clinical settings."
The full-text abstract is available on the Publications section of OncoSec's website (www.oncosec.com).
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "can," "may," "will," "suggest," "look forward to," "potential," "understand," and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, the following: uncertainties inherent in pre-clinical studies and clinical trials, such as the ability to enroll patients in clinical trials and the risk of adverse events; unexpected new data, safety and technical issues; our ability to raise additional funding necessary to fund continued operations; and the other factors discussed in OncoSec's filings with the Securities and Exchange Commission.
Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
CONTACT:
Investor Relations
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Media
Laura Radocaj
DGI Comm
212-825-3210
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-medicals-intratumoral-plasmid-il-12-demonstrates-effectiveness-at-enhancing-tumor-immunogenicity-in-preclinical-tumor-models-300427139.html
SOURCE OncoSec Medical Incorporated
